|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
Statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar
|
|
2
|
Halabi S, Kelly WK, Ma H, Zhou H, Solomon
NC, Fizazi K, Tangen CM, Rosenthal M, Petrylak DP and Hussain M:
Meta-analysis evaluating the impact of site of metastasis on
overall survival in men with castration-resistant prostate cancer.
J Clin Oncol. 34:1652–1659. 2016. View Article : Google Scholar
|
|
3
|
Schulman KL and Kohles J: Economic burden
of metastatic bone disease in the U.S. Cancer. 109:2334–2342. 2007.
View Article : Google Scholar
|
|
4
|
Grivennikov SI and Karin M: Inflammatory
cytokines in cancer: Tumour necrosis factor and interleukin 6 take
the stage. Ann Rheum Dis. 70(Suppl 1): i104–i108. 2011. View Article : Google Scholar
|
|
5
|
Landskron G, De la Fuente M, Thuwajit P,
Thuwajit C and Hermoso MA: Chronic inflammation and cytokines in
the tumor microenvironment. J Immunol Res. 2014.149185:2014.
|
|
6
|
De Marzo AM, Platz EA, Sutcliffe S, Xu J,
Grönberg H, Drake CG, Nakai Y, Isaacs WB and Nelson WG:
Inflammation in prostate carcinogenesis. Nat Rev Cancer. 7:256–269.
2007. View
Article : Google Scholar
|
|
7
|
Karan D and Dubey S: From inflammation to
prostate cancer: The role of inflammasomes. Adv Urol.
2016.3140372:2016.
|
|
8
|
Chung HW and Lim JB: High-mobility group
box-1 contributes tumor angiogenesis under interleukin-8 mediation
during gastric cancer progression. Cancer Sci. 108:1594–1601. 2017.
View Article : Google Scholar
|
|
9
|
Ke S, Zhou F, Yang H, Wei Y, Gong J, Mei
Z, Wu L, Yu H and Zhou Y: Downregulation of high mobility group box
1 modulates telomere homeostasis and increases the radiosensitivity
of human breast cancer cells. Int J Oncol. 46:1051–1058. 2015.
View Article : Google Scholar
|
|
10
|
Bald T, Quast T, Landsberg J, Rogava M,
Glodde N, Lopez-Ramos D, Kohlmeyer J, Riesenberg S, van den
Boorn-Konijnenberg D and Hömig-Hölzel C:
Ultraviolet-radiation-induced inflammation promotes angiotropism
and metastasis in melanoma. Nature. 507:109–113. 2014. View Article : Google Scholar
|
|
11
|
Li T, Gui Y, Yuan T, Liao G, Bian C, Jiang
Q, Huang S, Liu B and Wu D: Overexpression of high mobility group
box 1 with poor prognosis in patients after radical prostatectomy.
BJU Int. 110:E1125–E1130. 2012. View Article : Google Scholar
|
|
12
|
Gnanasekar M, Thirugnanam S and Ramaswamy
K: Short hairpin RNA (shRNA) constructs targeting high mobility
group box-1 (HMGB1) expression leads to inhibition of prostate
cancer cell survival and apoptosis. Int J Oncol. 34:425–431.
2009.
|
|
13
|
Gnanasekar M, Kalyanasundaram R, Zheng G,
Chen A, Bosland MC and Kajdacsy-Balla A: HMGB1: A promising
therapeutic target for prostate cancer. Prostate Cancer.
2013.157103:2013.
|
|
14
|
Kuniyasu H, Chihara Y, Kondo H, Ohmori H
and Ukai R: Amphoterin induction in prostatic stromal cells by
androgen deprivation is associated with metastatic prostate cancer.
Oncol Rep. 10:1863–1868. 2003.
|
|
15
|
Kalluri R and Weinberg RA: The basics of
epithelial-mesenchymal transition. J Clin Invest. 119:1420–1428.
2009. View
Article : Google Scholar
|
|
16
|
Larriba MJ, García de Herreros A and Muñoz
A: Vitamin D and the epithelial to mesenchymal transition. Stem
Cells Int. 2016.6213872:2016.
|
|
17
|
López-Novoa JM and Nieto MA: Inflammation
and EMT: An alliance towards organ fibrosis and cancer progression.
EMBO Mol Med. 1:303–314. 2009. View Article : Google Scholar
|
|
18
|
Wu Y, Deng J, Rychahou PG, Qiu S, Evers BM
and Zhou BP: Stabilization of snail by NF-kappaB is required for
inflammation-induced cell migration and invasion. Cancer Cell.
15:416–428. 2009. View Article : Google Scholar
|
|
19
|
Nisticò P, Bissell MJ and Radisky DC:
Epithelial-mesenchymal transition: General principles and
pathological relevance with special emphasis on the role of matrix
metalloproteinases. Cold Spring Harb Perspect Biol. 4:42012.
View Article : Google Scholar
|
|
20
|
Liu Z, Dou C, Wang Y, Jia Y, Li Q, Zheng
X, Yao Y, Liu Q and Song T: High mobility group box 1 has a
prognostic role and contributes to epithelial mesenchymal
transition in human hepatocellular carcinoma. Mol Med Rep.
12:5997–6004. 2015. View Article : Google Scholar
|
|
21
|
Zhu L, Li X, Chen Y, Fang J and Ge Z:
High-mobility group box 1: A novel inducer of the
epithelial-mesenchymal transition in colorectal carcinoma. Cancer
Lett. 357:527–534. 2015. View Article : Google Scholar
|
|
22
|
Bouvet V, Wuest M, Bailey JJ, Bergman C,
Janzen N, Valliant JF and Wuest F: Targeting prostate-specific
membrane antigen (PSMA) with F-18-labeled compounds: The influence
of prosthetic groups on tumor uptake and clearance profile. Mol
Imaging Biol. 19:923–932. 2017. View Article : Google Scholar
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
24
|
Kessenbrock K, Plaks V and Werb Z: Matrix
metalloproteinases: Regulators of the tumor microenvironment. Cell.
141:52–67. 2010. View Article : Google Scholar
|
|
25
|
Kang R, Chen R, Zhang Q, Hou W, Wu S, Cao
L, Huang J, Yu Y, Fan XG and Yan Z: HMGB1 in health and disease.
Mol Aspects Med. 40:1–116. 2014. View Article : Google Scholar
|
|
26
|
Lotze MT and Tracey KJ: High-mobility
group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal.
Nat Rev Immunol. 5:331–342. 2005. View Article : Google Scholar
|
|
27
|
Zhao CB, Bao JM, Lu YJ, Zhao T, Zhou XH,
Zheng DY and Zhao SC: Co-expression of RAGE and HMGB1 is associated
with cancer progression and poor patient outcome of prostate
cancer. Am J Cancer Res. 4:369–377. 2014.
|
|
28
|
Zhou J, Chen X, Gilvary DL, Tejera MM,
Eksioglu EA, Wei S and Djeu JY: HMGB1 induction of clusterin
creates a chemoresistant niche in human prostate tumor cells. Sci
Rep. 5:150852015. View Article : Google Scholar
|
|
29
|
Sims GP, Rowe DC, Rietdijk ST, Herbst R
and Coyle AJ: HMGB1 and RAGE in inflammation and cancer. Annu Rev
Immunol. 28:367–388. 2010. View Article : Google Scholar
|
|
30
|
Hollenbach M: The role of glyoxalase-I
(Glo-I), advanced glycation endproducts (AGEs), and their receptor
(RAGE) in chronic liver disease and hepatocellular carcinoma (HCC).
Int J Mol Sci. 18:182017. View Article : Google Scholar
|
|
31
|
Zhang J, Kou YB, Zhu JS, Chen WX and Li S:
Knockdown of HMGB1 inhibits growth and invasion of gastric cancer
cells through the NF-κB pathway in vitro and in vivo. Int J Oncol.
44:1268–1276. 2014. View Article : Google Scholar
|
|
32
|
Schlueter C, Weber H, Meyer B, Rogalla P,
Röser K, Hauke S and Bullerdiek J: Angiogenetic signaling through
hypoxia: HMGB1: an angiogenetic switch molecule. Am J Pathol.
166:1259–1263. 2005. View Article : Google Scholar
|
|
33
|
Bussemakers MJ, van de Ven WJ, Debruyne FM
and Schalken JA: Identification of high mobility group protein I(Y)
as potential progression marker for prostate cancer by differential
hybridization analysis. Cancer Res. 51:606–611. 1991.
|
|
34
|
Nestl A, Von Stein OD, Zatloukal K, Thies
WG, Herrlich P, Hofmann M and Sleeman JP: Gene expression patterns
associated with the metastatic phenotype in rodent and human
tumors. Cancer Res. 61:1569–1577. 2001.
|
|
35
|
Leman ES, Madigan MC, Brünagel G, Takaha
N, Coffey DS and Getzenberg RH: Nuclear matrix localization of high
mobility group protein I(Y) in a transgenic mouse model for
prostate cancer. J Cell Biochem. 88:599–608. 2003. View Article : Google Scholar
|
|
36
|
Ishiguro H, Nakaigawa N, Miyoshi Y,
Fujinami K, Kubota Y and Uemura H: Receptor for advanced glycation
end products (RAGE) and its ligand, amphoterin are overexpressed
and associated with prostate cancer development. Prostate.
64:92–100. 2005. View Article : Google Scholar
|
|
37
|
Feng A, Tu Z and Yin B: The effect of
HMGB1 on the clini-copathological and prognostic features of
non-small cell lung cancer. Oncotarget. 7:20507–20519. 2016.
View Article : Google Scholar
|
|
38
|
Melvin VS, Roemer SC, Churchill ME and
Edwards DP: The C-terminal extension (CTE) of the nuclear hormone
receptor DNA binding domain determines interactions and functional
response to the HMGB-1/-2 co-regulatory proteins. J Biol Chem.
277:25115–25124. 2002. View Article : Google Scholar
|
|
39
|
Verrijdt G, Haelens A, Schoenmakers E,
Rombauts W and Claessens F: Comparative analysis of the influence
of the high-mobility group box 1 protein on DNA binding and
transcriptional activation by the androgen, glucocorticoid,
progesterone and mineralocorticoid receptors. Biochem J.
361:97–103. 2002. View Article : Google Scholar
|
|
40
|
Findlay VJ, Turner DP, Yordy JS,
McCarragher B, Shriver MR, Szalai G, Watson PM, Larue AC, Moussa O
and Watson DK: Prostate-derived ETS factor regulates
epithelial-to-mesenchymal transition through both SLUG-dependent
and independent mechanisms. Genes Cancer. 2:120–129. 2011.
View Article : Google Scholar
|
|
41
|
Carver BS, Tran J, Chen Z, Carracedo-Perez
A, Alimonti A, Nardella C, Gopalan A, Scardino PT, Cordon-Cardo C,
Gerald W and Pandolfi PP: ETS rearrangements and prostate cancer
initiation. Nature. 457:E1–E3. 2009. View Article : Google Scholar
|
|
42
|
Karin M and Greten FR: NF-kappaB: Linking
inflammation and immunity to cancer development and progression.
Nat Rev Immunol. 5:749–759. 2005. View Article : Google Scholar
|
|
43
|
Liu PL, Tsai JR, Hwang JJ, Chou SH, Cheng
YJ, Lin FY, Chen YL, Hung CY, Chen WC and Chen YH: High-mobility
group box 1-mediated matrix metalloproteinase-9 expression in
non-small cell lung cancer contributes to tumor cell invasiveness.
Am J Respir Cell Mol Biol. 43:530–538. 2010. View Article : Google Scholar
|
|
44
|
Dominguez C, David JM and Palena C:
Epithelial-mesenchymal transition and inflammation at the site of
the primary tumor. Semin Cancer Biol. 47:177–184. 2017. View Article : Google Scholar
|
|
45
|
Thiery JP, Acloque H, Huang RY and Nieto
MA: Epithelial-mesenchymal transitions in development and disease.
Cell. 139:871–890. 2009. View Article : Google Scholar
|
|
46
|
Xia Li CW, Huo W, Lim L, Wu SO, Hsu Y,
Chao JL, Yamaguchi CH, Yang H and Ding NKQ: Epithelial-mesenchymal
transition induced by TNF-α requires NF-κB-mediated transcriptional
upregulation of Twist1. Cancer Res. 72:1290–1300. 2012. View Article : Google Scholar
|
|
47
|
Radisky DC, Levy DD, Littlepage LE, Liu H,
Nelson CM, Fata JE, Leake D, Godden EL, Albertson DG and Nieto MA:
Rac1b and reactive oxygen species mediate MMP-3-induced EMT and
genomic instability. Nature. 436:123–127. 2005. View Article : Google Scholar
|
|
48
|
Shetty AV, Thirugnanam S, Dakshinamoorthy
G, Samykutty A, Zheng G, Chen A, Bosland MC, Kajdacsy-Balla A and
Gnanasekar M: 18α-glycyrrhetinic acid targets prostate cancer cells
by downregulating inflammation-related genes. Int J Oncol.
39:635–640. 2011.
|
|
49
|
He Y, Zha J, Wang Y, Liu W, Yang X and Yu
P: Tissue damage-associated ‘danger signals’ influence T-cell
responses that promote the progression of preneoplasia to cancer.
Cancer Res. 73:629–639. 2013. View Article : Google Scholar
|
